Details
| Original language | English |
|---|---|
| Pages (from-to) | 4678-4679 |
| Number of pages | 2 |
| Journal | Journal of the American Chemical Society |
| Volume | 125 |
| Issue number | 16 |
| Publication status | Published - 23 Apr 2003 |
Abstract
UrdGT2 is a D-olivosyltransferase from the metabolic pathway of urdamycin A, an angucycline antitumor and antimicrobial drug. The remarkable feature of this biocatalyst is its ability to set up C-glycosidic bonds. Using an in vivo system suitable to deliver the trideoxysugar rhodinose in both D- and L- configuration we could verify that both have been accepted as substrates and attached to the urdamycin polyketide backbone via a C-glycosidic bond. Regardless of the stereochemistry, these C-glycosides served as acceptor for a subsequent glycosylation step to yield the novel urdamycins R and S with di-rhodinosyl side chains at C-9 of the polyketide moiety.
ASJC Scopus subject areas
- Chemical Engineering(all)
- Catalysis
- Chemistry(all)
- General Chemistry
- Biochemistry, Genetics and Molecular Biology(all)
- Biochemistry
- Chemical Engineering(all)
- Colloid and Surface Chemistry
Cite this
- Standard
- Harvard
- Apa
- Vancouver
- BibTeX
- RIS
In: Journal of the American Chemical Society, Vol. 125, No. 16, 23.04.2003, p. 4678-4679.
Research output: Contribution to journal › Article › Research › peer review
}
TY - JOUR
T1 - The C-glycosyltransferase UrdGT2 is unselective toward D- and L-configured nucleotide-bound rhodinoses
AU - Hoffmeister, Dirk
AU - Dräger, Gerald
AU - Ichinose, Koji
AU - Rohr, Jürgen
AU - Bechthold, Andreas
N1 - Copyright: Copyright 2010 Elsevier B.V., All rights reserved.
PY - 2003/4/23
Y1 - 2003/4/23
N2 - UrdGT2 is a D-olivosyltransferase from the metabolic pathway of urdamycin A, an angucycline antitumor and antimicrobial drug. The remarkable feature of this biocatalyst is its ability to set up C-glycosidic bonds. Using an in vivo system suitable to deliver the trideoxysugar rhodinose in both D- and L- configuration we could verify that both have been accepted as substrates and attached to the urdamycin polyketide backbone via a C-glycosidic bond. Regardless of the stereochemistry, these C-glycosides served as acceptor for a subsequent glycosylation step to yield the novel urdamycins R and S with di-rhodinosyl side chains at C-9 of the polyketide moiety.
AB - UrdGT2 is a D-olivosyltransferase from the metabolic pathway of urdamycin A, an angucycline antitumor and antimicrobial drug. The remarkable feature of this biocatalyst is its ability to set up C-glycosidic bonds. Using an in vivo system suitable to deliver the trideoxysugar rhodinose in both D- and L- configuration we could verify that both have been accepted as substrates and attached to the urdamycin polyketide backbone via a C-glycosidic bond. Regardless of the stereochemistry, these C-glycosides served as acceptor for a subsequent glycosylation step to yield the novel urdamycins R and S with di-rhodinosyl side chains at C-9 of the polyketide moiety.
UR - http://www.scopus.com/inward/record.url?scp=0242515829&partnerID=8YFLogxK
U2 - 10.1021/ja029645k
DO - 10.1021/ja029645k
M3 - Article
C2 - 12696864
AN - SCOPUS:0242515829
VL - 125
SP - 4678
EP - 4679
JO - Journal of the American Chemical Society
JF - Journal of the American Chemical Society
SN - 0002-7863
IS - 16
ER -